


Accepted Manuscript

Racial Differences in the Effects of Hormone Therapy on Incident Open-Angle
Glaucoma in a Randomized Trial

Ts Vajaranant, Rm Ray, Lr Pasquale, J.A. Mares, R. Ritch, Ew Gower, Mn Haan, Rd
Jackson, Pm Maki



PII: S0002-9394(18)30428-8

DOI: [10.1016/j.ajo.2018.07.035](https://doi.org/10.1016/j.ajo.2018.07.035)

Reference: AJOPHT 10606

To appear in: *American Journal of Ophthalmology*

Received Date: 7 April 2018

Revised Date: 20 July 2018

Accepted Date: 25 July 2018

Please cite this article as: Vajaranant T, Ray R, Pasquale L, Mares J, Ritch R, Gower E, Haan M, Jackson R, Maki P, Racial Differences in the Effects of Hormone Therapy on Incident Open-Angle Glaucoma in a Randomized Trial, *American Journal of Ophthalmology* (2018), doi: 10.1016/j.ajo.2018.07.035.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Purpose: We conducted a secondary analysis of a randomized, placebo-controlled trial to test if hormone therapy (HT) altered the risk of open-angle glaucoma (OAG), and if the risk reduction varied by race. **Design:** Secondary analysis of randomized controlled trial data **Methods:** We linked Medicare claims data to 25,535 women in the Women's Health Initiative. Women without a uterus were randomized to receive either oral conjugated equine estrogens (CEE 0.625mg/day) or placebo, and women with a uterus received oral CEE and medroxyprogesterone acetate (CEE 0.625mg/day+MPA 2.5mg/day) or placebo. We used Cox proportional hazards models to calculate hazard ratios (HR) and 95% confidence interval. **Results:** After excluding women with prevalent glaucoma or without claims for eye-care provider visits, the final analysis included 8,102 women (mean age=68.5±4.8 years). The OAG incidence was 7.6% (mean follow-up=11.5±5.2 years; mean HT duration=4.4±2.3 years). Increased age (p-trend=0.01) and African-American race (HR=2.69, 95%CI=2.13 to 3.42; Caucasian as a reference) were significant risk factors for incident OAG. We found no overall benefit of HT in reducing incident OAG (HR=1.01, 95%CI=0.79-1.29 in the CEE trial, and HR=1.05, 95%CI=0.85-1.29 in the CEE+MPA trial). However, race modified the relationship between CEE use and OAG risk (p-interaction=0.01), and risk was reduced in African-American women treated with CEE (HR=0.49, 95%CI=0.27-0.88), compared to placebo. Race did not modify the relation between CEE+MPA use and OAG risk (p-interaction=0.68). **Conclusions:** Analysis suggests that HT containing estrogen, but not a combination of estrogen and progesterone, reduces the risk of incident OAG among African-American women. Further investigation is needed.

Download English Version:

<https://daneshyari.com/en/article/10138094>

Download Persian Version:

<https://daneshyari.com/article/10138094>

[Daneshyari.com](https://daneshyari.com)